Overview
This Randomized Controlled Trial was to clarity the clinical feasibility of 3D-HDRA results in guiding the drug use of interventional chemotherapy after primary liver cancer surgery.
Description
Data of Patients who received 3D-HDRA after primary liver cancer radical reaction and received Transarterial Chemoembolization #will be collected #excluding incomplete data.
The primary endpoint was the one-year disease-free survival(DFS) rate #Secondary endpoint was the adverse event.
Eligibility
Inclusion Criteria:
- Patients voluntarily cooperated with the study and signed an informed consent form.
- Any gender, age 18 or older, 75 or younger.
- Patients who need to confirm the maximum tumor load (the maximum diameter of a single tumor lesion) before performing radical surgery; patients with a confirmed diagnosis of primary liver cancer after postoperative pathological histological examination.
- Patients with R0 resection confirmed by imaging and pathology (no residual lesions and complete tumor resection after radical surgery).
- Child-Pugh score of 5-7 (A or B), patients with a score of 7 must be free of ascites.
- ECOG physical fitness status score of 0-1.
- Women of childbearing age with a negative pregnancy test and willing to use effective contraception for the duration of the study.
Exclusion Criteria:
- Patients with recurrent liver cancer.
- Patients with existing extrahepatic distant metastases (including local lymph node metastases or distant organ metastases: e.g., lung, brain, bone, etc.) at the time of diagnosis.
- Treatment with other experimental drugs or other interventions after radical resection.
- Patients with other malignant tumors that have not been cured within 5 years.
- Patients with non-radical resections (R1 and R2 resections).
- Patients with residual or recurrent lesions detected on imaging within 1-2 months after surgery.
- Patients in whom death occurred within 30 days after surgery.